PA
CHRS icon

Profund Advisors’s Coherus Oncology CHRS Stock Holding History

Profund Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-145,989
Closed -$546K – 1138
2023
Q3 		$546K Buy
+145,989
New +$674K 0.03% 443
2023
Q2 		– Sell
-77,101
Closed -$527K – 1088
2023
Q1 		$527K Buy
+77,101
New +$598K 0.03% 483

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Profund Advisors's CHRS Position: Q4 2023 in Review

Profund Advisors sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 145,989 shares — an estimated $546K sold.

Profund Advisors first reported a position in CHRS in Q1 2023 and held it in 2 quarters. The position peaked at $546K in Q3 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Profund Advisors reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Profund Advisors sold 145,989 Coherus Oncology shares in Q4 2023, an estimated $546K.
  • Profund Advisors first reported a position in Coherus Oncology in Q1 2023 and held it in 2 quarters.
  • Profund Advisors's Coherus Oncology position peaked at $546K in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Profund Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.